IM Cannabis (IMCC) Equity Income (2020 - 2021)
IM Cannabis' (IMCC) quarterly Equity Income came in at $4.5 million in Q3 2021, up 711.32% year-on-year from $553812.7 in Q3 2020, and up 8.53% quarter-over-quarter from $4.1 million in Q2 2021.
IM Cannabis (IMCC) Equity Income (2020 - 2021) Analysis & Trends
IM Cannabis' Equity Income history runs 2 years deep, the most recent figure standing at $4.5 million for Q3 2021.
- On a quarterly basis, Equity Income rose 711.32% year-over-year to $4.5 million in Q3 2021; TTM through Sep 2021 was $24.5 million, a N/A change from a year earlier, with the FY2020 full-year figure at $21.4 million, changed N/A from the prior year.
- Equity Income improved to $4.5 million in Q3 2021 per IMCC's latest filing, from $4.1 million in the prior quarter.
- Across five years, Equity Income topped out at $15.3 million in Q4 2020 and bottomed at $553812.7 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | IM Cannabis | 554,496.00 | -177,626.51 | 1.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 4.49 Mn |
| Jun 30, 2021 | 4.14 Mn |
| Dec 31, 2020 | 15.32 Mn |
| Sep 30, 2020 | 553,812.67 |
| Jun 30, 2020 | 6.99 Mn |